Arbutus Biopharma Corp. Daily Stock Analysis

Daily Stock Analysis, ABUS, Arbutus Biopharma Corp, priceseries

Arbutus Biopharma Corp. Daily Stock Analysis
Stock Information
Open
2.84
Close
2.83
High
2.96
Low
2.81
Previous Close
2.81
Daily Price Gain
0.02
YTD High
4.01
YTD High Date
Jan 3, 2022
YTD Low
2.38
YTD Low Date
Jan 28, 2022
YTD Price Change
-1.15
YTD Gain
-28.89%
52 Week High
6.50
52 Week High Date
Dec 1, 2021
52 Week Low
2.38
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-0.41
52 Week Gain
-12.65%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 22. 2017
3.70
Sep 12. 2017
4.29
14 Trading Days
16.04%
Link
LONG
Sep 13. 2017
4.50
Oct 2. 2017
5.97
13 Trading Days
32.63%
Link
LONG
May 2. 2018
5.70
May 18. 2018
6.09
12 Trading Days
6.82%
Link
LONG
Jun 22. 2018
6.80
Jul 24. 2018
10.95
21 Trading Days
61.03%
Link
LONG
Nov 6. 2018
4.75
Nov 9. 2018
5.04
3 Trading Days
6.00%
Link
LONG
Sep 3. 2019
1.44
Sep 18. 2019
1.63
11 Trading Days
13.41%
Link
LONG
Dec 3. 2019
2.00
Dec 16. 2019
2.23
9 Trading Days
11.55%
Link
LONG
Dec 30. 2019
2.73
Jan 24. 2020
2.97
17 Trading Days
8.61%
Link
LONG
May 12. 2020
1.65
Jun 2. 2020
2.03
14 Trading Days
22.77%
Link
LONG
Jul 15. 2020
1.89
Jul 31. 2020
3.90
12 Trading Days
106.48%
Link
LONG
Sep 14. 2020
2.62
Oct 2. 2020
3.04
14 Trading Days
15.98%
Link
LONG
Nov 9. 2020
3.18
Nov 18. 2020
3.40
7 Trading Days
7.04%
Link
LONG
Nov 25. 2020
3.77
Dec 2. 2020
3.96
4 Trading Days
5.04%
Link
LONG
Dec 11. 2020
3.91
Dec 21. 2020
4.17
6 Trading Days
6.78%
Link
LONG
Aug 23. 2021
3.11
Sep 28. 2021
4.29
25 Trading Days
37.92%
Link
Company Information
Stock Symbol
ABUS
Exchange
NasdaqGS
Company URL
http://www.arbutusbio.com
Company Phone
-
CEO
Mark J. Murray
Headquarters
-
Business Address
-
Sector
Healthcare
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

Arbutus Biopharma Corp. is a biopharmaceutical company. It focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading